ATE267258T1 - Impfstoffe für das respiratorische-synzytial- virus mit nuklein säuren - Google Patents

Impfstoffe für das respiratorische-synzytial- virus mit nuklein säuren

Info

Publication number
ATE267258T1
ATE267258T1 AT96918542T AT96918542T ATE267258T1 AT E267258 T1 ATE267258 T1 AT E267258T1 AT 96918542 T AT96918542 T AT 96918542T AT 96918542 T AT96918542 T AT 96918542T AT E267258 T1 ATE267258 T1 AT E267258T1
Authority
AT
Austria
Prior art keywords
rsv
vectors
respiratory
virus
synzytial
Prior art date
Application number
AT96918542T
Other languages
English (en)
Inventor
Xiaomao Li
Mary E Ewasyshyn
Suryaprakash Sambhara
Michel H Klein
Original Assignee
Aventis Pasteur
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23891664&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE267258(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Aventis Pasteur filed Critical Aventis Pasteur
Application granted granted Critical
Publication of ATE267258T1 publication Critical patent/ATE267258T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18522—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT96918542T 1995-06-07 1996-06-07 Impfstoffe für das respiratorische-synzytial- virus mit nuklein säuren ATE267258T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/476,397 US6019980A (en) 1995-06-07 1995-06-07 Nucleic acid respiratory syncytial virus vaccines
PCT/CA1996/000398 WO1996040945A2 (en) 1995-06-07 1996-06-07 Nucleic acid respiratory syncytial virus vaccines

Publications (1)

Publication Number Publication Date
ATE267258T1 true ATE267258T1 (de) 2004-06-15

Family

ID=23891664

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96918542T ATE267258T1 (de) 1995-06-07 1996-06-07 Impfstoffe für das respiratorische-synzytial- virus mit nuklein säuren

Country Status (9)

Country Link
US (5) US6019980A (de)
EP (1) EP0832253B9 (de)
JP (1) JPH11507808A (de)
AT (1) ATE267258T1 (de)
AU (1) AU695527B2 (de)
BR (1) BR9608615A (de)
CA (1) CA2223610A1 (de)
DE (1) DE69632536D1 (de)
WO (1) WO1996040945A2 (de)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7465574B2 (en) 1994-09-30 2008-12-16 Medimmune, Llc Recombinant RSV virus expression systems and vaccines
US6083925A (en) * 1995-06-07 2000-07-04 Connaught Laboratories Limited Nucleic acid respiratory syncytial virus vaccines
FR2751229B1 (fr) 1996-07-19 1998-11-27 Rhone Merieux Formule de vaccin polynucleotidique notamment contre la pathologie respiratoire des bovins
US20060002949A1 (en) 1996-11-14 2006-01-05 Army Govt. Of The Usa, As Rep. By Secretary Of The Office Of The Command Judge Advocate, Hq Usamrmc. Transcutaneous immunization without heterologous adjuvant
US5980898A (en) 1996-11-14 1999-11-09 The United States Of America As Represented By The U.S. Army Medical Research & Material Command Adjuvant for transcutaneous immunization
US6797276B1 (en) 1996-11-14 2004-09-28 The United States Of America As Represented By The Secretary Of The Army Use of penetration enhancers and barrier disruption agents to enhance the transcutaneous immune response
US6060308A (en) * 1997-09-04 2000-05-09 Connaught Laboratories Limited RNA respiratory syncytial virus vaccines
US6830748B1 (en) 1997-09-26 2004-12-14 Medimmune Vaccines, Inc. Recombinant RSV virus expression systems and vaccines
DK1029069T3 (da) * 1997-11-14 2006-12-18 Sanofi Pasteur Ltd Alphavirus-vektor
EP1707633A1 (de) * 1997-11-14 2006-10-04 Sanofi Pasteur Limited Alphavirus-Vektoren als Impfstoffe gegen Paramyxovirus
WO1999025858A1 (en) * 1997-11-14 1999-05-27 Connaught Laboratories Limited Alphavirus vectors for paramyxovirus vaccines
FR2772047B1 (fr) 1997-12-05 2004-04-09 Ct Nat D Etudes Veterinaires E Sequence genomique et polypeptides de circovirus associe a la maladie de l'amaigrissement du porcelet (map), applications au diagnostic et a la prevention et/ou au traitement de l'infection
US6656906B1 (en) * 1998-05-20 2003-12-02 Trimeris, Inc. Hybrid polypeptides with enhanced pharmacokinetic properties
US6258782B1 (en) 1998-05-20 2001-07-10 Trimeris, Inc. Hybrid polypeptides with enhanced pharmacokinetic properties
AR030019A1 (es) * 1999-05-18 2003-08-13 Smithkline Beecham Corp Anticuerpos monoclonales humanos y fragmentos funcionales del mismo, un procedimiento para su produccion, composiciones farmaceuticas que los comprenden, una molecula aislada de acido nucleico, un plasmido recombinante, una celula hospedante y el uso de dichos anticuerpos para la manufactura de un m
US6943152B1 (en) 1999-06-10 2005-09-13 Merial DNA vaccine-PCV
PT1233782E (pt) * 1999-12-01 2009-02-13 Novartis Vaccines & Diagnostic Estimulação da produção de anticorpos específicos para o hcv
ES2170622B1 (es) * 1999-12-03 2004-05-16 Consejo Superior De Investigaciones Cientificas Clones y vectores infectivos derivados de coronavirus y sus aplicaciones.
AU784131B2 (en) * 1999-12-22 2006-02-09 Darrell R. Galloway Methods for protecting against lethal infection with bacillus anthracis
US6852705B2 (en) 2000-01-21 2005-02-08 Merial DNA vaccines for farm animals, in particular bovines and porcines
US7078388B2 (en) * 2000-01-21 2006-07-18 Merial DNA vaccines for farm animals, in particular bovines and porcines
DE60136334D1 (en) 2000-02-02 2008-12-11 Us Health Cd40-ligand als adjuvant für respiratorisches syncytialvirus-impfstoff
US6623741B1 (en) * 2000-02-29 2003-09-23 Trimeris, Inc. Methods and compositions for inhibition of membrane fusion-associated events including RSV transmission
US6686188B2 (en) 2000-05-26 2004-02-03 Amersham Plc Polynucleotide encoding a human myosin-like polypeptide expressed predominantly in heart and muscle
US6656700B2 (en) 2000-05-26 2003-12-02 Amersham Plc Isoforms of human pregnancy-associated protein-E
US20020123474A1 (en) * 2000-10-04 2002-09-05 Shannon Mark E. Human GTP-Rho binding protein2
EP1372708B1 (de) 2001-02-13 2008-06-18 GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY OF THE ARMY Impstoffe zur transkutanen immunisierung gegen reisediarrhö
TW200636064A (en) * 2004-10-28 2006-10-16 Centocor Inc Anti-respiratory syncytial virus antibodies, antigens and uses thereof
US7118427B2 (en) * 2004-12-30 2006-10-10 Homac Mfg Company Electrical connector including removable tether and cap assemblies and associated methods
ES2335360T3 (es) * 2005-11-25 2010-03-25 Galapagos Sas Derivados de urea utiles como moduladores de los receptores de calcio.
DE102006060799A1 (de) * 2006-12-21 2008-06-26 RUHR-UNIVERSITäT BOCHUM RSV F-Protein und seine Verwendung
US7947274B2 (en) 2007-01-04 2011-05-24 Humabs, LLC. Human cytomegalovirus neutralising antibodies and use thereof
GB0700133D0 (en) 2007-01-04 2007-02-14 Humabs Llc Human cytomegalovirus neutralising antibodies and use thereof
US20110008329A1 (en) * 2007-06-26 2011-01-13 Medlmmune, Llc Methods of Treating RSV Infections And Related Conditions
PL3009449T3 (pl) 2008-07-16 2018-09-28 Institute For Research In Biomedicine Przeciwciała neutralizujące ludzkie cytomegalowirusy i ich zastosowanie
US8460680B2 (en) * 2009-04-24 2013-06-11 National Health Research Institutes Polyvalent chimeric rubella virus-based vaccines
RU2012131014A (ru) 2009-12-21 2014-01-27 Корнелл Юниверсити Композиции нового пневмовируса и способы их применения
EA201891945A3 (ru) 2012-08-01 2019-05-31 Бавариан Нордик А/С Вакцина рекомбинантного модифицированного вируса осповакцины анкара (mva) респираторно-синцитиального вируса (rsv)
EP3035959A1 (de) 2013-08-21 2016-06-29 CureVac AG Kombinationsimpfstoff
EP3586871A3 (de) 2013-08-21 2020-03-11 CureVac AG Impfstoff gegen das respiratorische synzytialvirus
CA2925281C (en) 2013-09-25 2022-05-03 Zoetis Services Llc Pcv2b divergent vaccine composition and methods of use
DK3134131T3 (en) 2014-04-23 2022-02-07 Modernatx Inc Nucleic acid vaccines
EP3718565B1 (de) 2015-10-22 2022-04-27 ModernaTX, Inc. Impfstoffe gegen atemwegsvirus
US10626126B2 (en) * 2016-04-08 2020-04-21 Pulmocide Limited Compounds
WO2018170260A1 (en) 2017-03-15 2018-09-20 Modernatx, Inc. Respiratory syncytial virus vaccine
EP3746090A4 (de) * 2018-01-29 2021-11-17 ModernaTX, Inc. Rsv-rns-impfstoffe
EP4227319B1 (de) 2018-04-17 2025-11-26 CureVac SE Neuartige rsv-rna-moleküle und zusammensetzungen zur impfung

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5149650A (en) * 1986-01-14 1992-09-22 University Of North Carolina At Chapel Hill Vaccines for human respiratory virus
CA2357538A1 (en) 1989-03-21 1990-10-04 Wisconsin Alumni Research Foundation Expression of exogenous polynucleotide sequences in a vertebrate
US5703055A (en) * 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5195510A (en) * 1990-07-30 1993-03-23 Svacina Lawrence M Deep pressure massage device
WO1992007940A2 (en) * 1990-11-05 1992-05-14 Siba Kumar Samal Bovine respiratory syncytial virus genes
JPH06510524A (ja) * 1991-05-14 1994-11-24 ユニバーシティ オブ コネチカット 免疫原性タンパク質をコードする遺伝子の標的への配達
IL105456A (en) * 1992-04-21 1996-12-05 American Home Prod Vaccines of attenuated respiratory syncytial virus
IL108915A0 (en) 1993-03-18 1994-06-24 Merck & Co Inc Polynucleotide vaccine against influenza virus
AU689489B2 (en) * 1993-07-30 1998-04-02 Oravax, Inc Monoclonal IgA antibody against respiratory syncytial virus

Also Published As

Publication number Publication date
CA2223610A1 (en) 1996-12-19
AU695527B2 (en) 1998-08-13
US6022864A (en) 2000-02-08
EP0832253B1 (de) 2004-05-19
BR9608615A (pt) 1999-06-15
DE69632536D1 (de) 2004-06-24
US6677127B1 (en) 2004-01-13
WO1996040945A3 (en) 1997-01-23
AU6117696A (en) 1996-12-30
US5880104A (en) 1999-03-09
US5843913A (en) 1998-12-01
WO1996040945A2 (en) 1996-12-19
EP0832253B9 (de) 2004-12-22
EP0832253A2 (de) 1998-04-01
JPH11507808A (ja) 1999-07-13
US6019980A (en) 2000-02-01

Similar Documents

Publication Publication Date Title
ATE267258T1 (de) Impfstoffe für das respiratorische-synzytial- virus mit nuklein säuren
MXPA01008966A (es) Vacunas contra el virus sincicial respiratorio a base de acido nucleico.
IL141623A0 (en) Method of dna vaccination
GB9224584D0 (en) Use of outer membrane protein d15 and its peptides as vaccine against haempohilus influenzae diseases
ES557358A0 (es) Un metodo para la deteccion de anticuerpos especificos de un virus lav en un fluido biologico.
EE200200709A (et) Liitvalku sisaldava kompositsiooni ning seda liitvalku ja liitpolüpeptiidi kodeeriva nukleiinhappe kasutamine
ZA837603B (en) Immunogenic protein or peptide complex,method of producing said complex and the use thereof as an immune stimulant and as a vaccine
DE69829668D1 (de) Herstellung und verwendung von rekombinanten influenza a virus m2 konstruktionen und impstoffe
ZA91134B (en) New proteins produced by human lymphocytes,dna sequence encoding these proteins and their pharmaceutical and biological uses
ATE127345T1 (de) Stressproteine und verwendungen dafür.
ATE205254T1 (de) Transformierender wachstumsfaktor alpha h1
DE69734882D1 (de) Dna immunisierung gegen chlamydia infektion
WO1996021734A3 (en) P15 and tyrosinase melanoma antigens and their use in diagnostic and therapeutic methods
DE69737413D1 (en) Bakterioferritin aus helicobacter pylori
NZ500540A (en) Purified proteins, fusion proteins, recombinant vector, vaccine, kit, comprising proteins from Actinobacillus pleuropneumoniae
DK610888D0 (da) Cardiodilatinfragmentet, fremgangsmaade til fremstilling deraf samt dets anvendelse
GR860915B (en) Expression and diagnostic use of gag encoded peptides which are immunologically reactive with antibodies to lav
BR9815496A (pt) Vacinas de ácido nucléico que codificam proteìna gde vìrus sincicial respiratório
IE870507L (en) Bovine virus diarrhea and hog cholera vaccines
HU9200583D0 (en) Method for producing el peptides of rubeola
IE890087L (en) Recombinant human interleukin-1 alpha polypeptides
MX9709525A (es) Vacunas de virus sincicial respiratorio de acido nucleico.
WO1995020658A3 (en) Diagnosis and treatment of infections due to streptococci and enterococci
CA2284110A1 (en) An ex vivo animal or challenge model as method to measure protective immunity directed against parasites and vaccines shown to be protective in said method
WO2002060390A3 (en) Induction of immune responses to isoaspartyl-modified antigens

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties